依那西普与甲氨蝶呤联合用药方案治疗类风湿关节炎的临床评价

Clinical Evaluation of Etanercept Combined with Methotrexate in the Treatment of Rheumatoid Arthritis

目的 :探讨依那西普与甲氨蝶呤联合用药对类风湿关节炎的疗效。方法 :选取我院类风湿关节炎患者80例,按随机数字表法分为两组,各40例。对照组给予甲氨蝶呤(10 mg,qwd)治疗,观察组给予依那西普(25 mg,biw)联合甲氨蝶呤(10 mg,qwd)治疗。结果:治疗后,观察组肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1以及超敏C-反应蛋白(hs-CRP)水平低于对照组(P<0.05);观察组自体细胞再生(ACR)症状好转20%(ACR20)率、ACR50率、ACR70率均优于对照组,差异有统计学意义(P<0.05);治疗后,观察组总不良反应发生率明显低于对照组,差异有统计学意义(P<0.05);观察组类风湿因子水平、C反应蛋白水平、关节肿胀个数均低于对照组(P<0.05)。结论 :依那西普联合甲氨蝶呤治疗可提高类风湿关节炎患者治疗效果,用药安全性较高。

Objective:To explore the therapeutic effect of etanercept in combination with methotrexate. Methods:80 patients suffering from rheumatoid arthritis in Puyang Olifield General Hospital were randomly divided into two groups with 40 cases in each group. Patients in the control group were treated with methotrexate(10 mg, qwd), while patients in the observation group were treated with etanercept(25 mg, biw) combined with methotrexate(10 mg, qwd). Results:After treatment, levels of tumor necrosis factor(TNF)-α, interleukin(IL)-1 and hypersensitive C-reactive protein(hs-CRP) in the observation group were significantly lower than those in the control group(P<0.05). The observation group achieved higher autogenous cell rejuvenation(ACR)20、ACR50 and ACR70 response rate than the control group, and the difference between the two groups was statistically significant(P<0.05). Moreover, the total incidence of adverse drug reaction in the observation group after treatment was significantly lower than that of the control group(P<0.05), and the levels of rheumatoid factor, C-reactive protein and joint swelling number in the observation group were significantly lower than those of the control group(P<0.05). Conclusion:In the treatment of rheumatoid arthritis patients, etanercept combined with methotrexate could improve the therapeutic efficiency with higher medication safety.